PDS Biotechnology to Present at the HC Wainwright 23rd Annual Global Investment Conference
PDS Biotechnology Corporation (Nasdaq: PDSB) announced its participation in the HC Wainwright 23rd Annual Global Investment Conference, set for September 13-15, 2021. The management will present updates on three ongoing Phase 2 clinical trials for PDS0101, along with progress on PDS0102 and PDS0103, which are entering human clinical trials. The presentation will be available on demand starting September 13 at 7:00 am EDT on the company’s website. PDS Biotech specializes in immunotherapy based on its Versamune® technology, targeting various cancers including breast and lung cancer.
- None.
- None.
FLORHAM PARK, N.J., Sept. 07, 2021 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies based on the Company’s proprietary Versamune® T-cell activating technology, announced today that its management will present at the HC Wainwright 23rd Annual Global Investment Conference.
The presentation will provide an update on the three ongoing PDS0101 Phase 2 clinical trials. The talk will also provide updates on progression of two other investigational pipeline products PDS0102 (Versamune®-TARP) and PDS0103 (Versamune®-MUC1) into human clinical trials. The conference is taking place virtually from September 13 - 15, 2021.
HC Wainwright 23rd Annual Global Investment Conference:
Investors can register for the conference HERE.
The presentation will be available on demand beginning at 7:00 am EDT on Monday, September 13, 2021 within the Investor section of the company’s website, https://pdsbiotech.com/.
About PDS Biotechnology
PDS Biotech is a clinical-stage immunotherapy company developing a growing pipeline of cancer immunotherapies based on the Company’s proprietary Versamune® T-cell activating technology platform. Our Versamune®-based products have demonstrated the potential to overcome the limitations of current immunotherapy by inducing in vivo, large quantities of high-quality, highly potent polyfunctional tumor specific CD4+ helper and CD8+ killer T-cells. PDS Biotech has developed multiple therapies, based on combinations of Versamune® and disease-specific antigens, designed to train the immune system to better recognize diseased cells and effectively attack and destroy them. The company’s pipeline products address various cancers including breast, colon, lung, prostate and ovarian cancers. To learn more, please visit www.pdsbiotech.com or follow us on Twitter at @PDSBiotech.
About PDS0101
PDS Biotech’s lead candidate, PDS0101, combines the utility of the Versamune® platform with targeted antigens in HPV-expressing cancers. In partnership with Merck & Co., PDS Biotech is evaluating a combination of PDS0101 and KEYTRUDA® in a Phase 2 study in first-line treatment of recurrent or metastatic head and neck cancer. PDS Biotech is also conducting two additional Phase 2 studies in advanced HPV-associated cancers and advanced localized cervical cancer with the National Cancer Institute (NCI) and The University of Texas MD Anderson Cancer Center, respectively.
Media & Investor Relations Contact:
Deanne Randolph
PDS Biotech
Phone: +1 (908) 517-3613
Email: drandolph@pdsbiotech.com
Rich Cockrell
CG Capital
Phone: +1 (404) 736-3838
Email: rich@cg.capital
FAQ
When is the HC Wainwright 23rd Annual Global Investment Conference for PDSB?
What updates will PDSB present at the conference?
Where can I watch the PDSB presentation?
What is PDS0101 and what is its significance for PDSB?
What technology does PDSB use for its cancer therapies?
